High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas.

Background: No serum marker is currently available for the diagnosis and treatment of gliomas. Plasminogen activator inhibitor-1 (PAI-1) controls the proteolytic activity in cancer cells and cellular migration during angiogenesis.

Patients And Methods: To verify the potential of PAI-1 as a serum marker for gliomas, the serum PAI-1 concentrations were measured by ELISA in 57 glioma patients and 34 healthy volunteers.

Overexpression of PAX5 in oral carcinogenesis.

The oncogenic transcription factor PAX5 is an important developmental regulator and is implicated in the pathogenesis of several malignancies. The PAX5 gene is involved in medulloblastoma, non-Hodgkin's lymphoma, transitional cell carcinoma of the bladder, neuroblastoma, breast cancer and SCC. In the current study, to determine the potential involvement of PAX5 in oral squamous-cell carcinoma (OSCC) and leukoplakias, we evaluated the status of PAX5 mRNA and protein expression in OSCC cell lines, human primary OSCCs, and leukoplakias by real-time quantitative reverse transcriptase-polymerase chain reaction, Western blot analysis, and immunohistochemistry.

Nanoscopic behavior of polyvinylpyrrolidone particles on polysulfone/polyvinylpyrrolidone film.

We revealed morphology and physicochemical behavior of a widely used powerful hydrophilizing agent, polyvinylpyrrolidone (PVP), present on polysulfone (PS)/PVP films by atomic force microscopy (AFM). This is the first time such clear PS/PVP phase-separated morphology was observed by nanoscopic technique. The film surfaces were observed by the identical observation mode, probe and scanning conditions to reveal the change of PVP morphology and behavior between dry and wet conditions.